Evidence map›Paper›PMID 41256260›Full record

ArticleFrontiers in pharmacology2025

Multi-omics analysis elucidates the therapeutic mechanisms of the Quzhi formula in metabolic dysfunction-associated steatohepatitis targeting gut microbiota, lipid metabolism, and the role of its metabolite fraxin.

Jiao-Xiang Wu, Yue-Lan Wu, Mei-Fang Li, Nian Liu, Ying Liu, Yan-Ping Huang, Yuan Gan, Xiao-Yu Wang, Hai-Sheng Chai, Jin Xu and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jiao-Xiang Wu *Phase I Clinical Trial Unit and Department of Infectious Diseases and Department of Clinical Laboratory and Plastic Surgery Department, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yue-Lan Wu *Phase I Clinical Trial Unit and Department of Infectious Diseases and Department of Clinical Laboratory and Plastic Surgery Department, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Mei-Fang LiHenan University, Zhengzhou, China.
Nian LiueHealth Program of Shanghai Anti-doping Laboratory, Shanghai University of Sport, Shanghai, China.
Ying LiuClinical College of Traditional Chinese Medicine, Gansu University of Chinese Medicine, Lanzhou, China.
Yan-Ping HuangPhase I Clinical Trial Unit and Department of Infectious Diseases and Department of Clinical Laboratory and Plastic Surgery Department, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yuan GanPhase I Clinical Trial Unit and Department of Infectious Diseases and Department of Clinical Laboratory and Plastic Surgery Department, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiao-Yu WangPhase I Clinical Trial Unit and Department of Infectious Diseases and Department of Clinical Laboratory and Plastic Surgery Department, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Hai-Sheng ChaiYueyang Integrated Chinese and Western Medicine Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Jin XuPhase I Clinical Trial Unit and Department of Infectious Diseases and Department of Clinical Laboratory and Plastic Surgery Department, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Qian XiDepartment of Endocrinology, Shanghai Pudong New Area Gongli Hospital, Shanghai, China.
Xi-Rong GuoPhase I Clinical Trial Unit and Department of Infectious Diseases and Department of Clinical Laboratory and Plastic Surgery Department, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Hui-Ming ShengPhase I Clinical Trial Unit and Department of Infectious Diseases and Department of Clinical Laboratory and Plastic Surgery Department, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ting-Ting ShenPhase I Clinical Trial Unit and Department of Infectious Diseases and Department of Clinical Laboratory and Plastic Surgery Department, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Qin ZhangPhase I Clinical Trial Unit and Department of Infectious Diseases and Department of Clinical Laboratory and Plastic Surgery Department, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Funding

Penn State Clinical and Translational Science InstituteUL1TR002014 · NCATS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI KRASCHNEWSKI, JENNIFER L. · 2016 to 2025
$33.7M
NCATS NIH HHS UL1 TR002014
6 · The paper itself

Abstract

Metabolic dysfunction-associated steatohepatitis (MASH) is an advanced stage of fatty liver disease with no approved pharmacotherapies. The Quzhi Formula (QZF), a traditional Chinese medicine utilized clinically for nearly two decades, has shown promising efficacy against MASH; however, its mechanisms of action remain largely unexplored. To elucidate these mechanisms, we conducted a multi-omics investigation integrating 16S rRNA sequencing, untargeted metabolomics, and transcriptomics in a MASH mouse model, with findings validated by histology. QZF treatment significantly alleviated hepatic steatosis, restored gut microbial diversity, and suppressed the proliferation of

Indexed as

AMPKautophagyfraxinmetabolic dysfunction-associated steatohepatitis (MASH)Quzhi formula (QZF)

Identifiers

PMID41256260
PMCPMC12620365

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.